19.2 Painless Vision Loss & Chronic Ophthalmic Disease
Key Takeaways
- Macular degeneration, retinal detachment, diabetic retinopathy, amaurosis fugax, temporal arteritis and Roth spots are enumerated under retinal disease.
- Central retinal artery occlusion is a stroke equivalent requiring urgent evaluation for a cardioembolic or carotid source.
- Giant cell arteritis must be excluded in any patient over 50 with acute vision loss, and corticosteroids are started before biopsy.
- Retinal detachment presents with flashes, floaters and a curtain-like field defect and requires urgent ophthalmology referral.
- Annual dilated eye examination is recommended in diabetes because retinopathy is asymptomatic until advanced.
Last updated: August 2026
1. Painless Acute Vision Loss
Sudden, painless, monocular vision loss is a medical emergency requiring rapid diagnostic differentiation between arterial vascular occlusion, venous thrombosis, systemic inflammatory vasculitis, and mechanical retinal detachment.
| Condition | Pathophysiology & Etiology | Funduscopic Hallmarks | Key Diagnostic Workup | Emergency Management |
|---|---|---|---|---|
| Central Retinal Artery Occlusion (CRAO) | Embolic occlusion of central retinal artery (internal carotid artery atheroma, cardiogenic embolus, calcific valve plaque) | Diffusely pale, ischemic white/edematous retina with a distinct "Cherry-Red Spot" at the fovea; segmentation / "boxcarring" of retinal blood columns | Emergency Stroke Protocol: Carotid duplex ultrasound, Echocardiogram (TTE/TEE), Continuous ECG telemetry, MRI brain/DWI, ESR/CRP | Emergency stroke center admission; ocular massage, anterior chamber paracentesis (variable benefit); secondary stroke prevention (antiplatelet, statin, BP control) |
| Central Retinal Vein Occlusion (CRVO) | Thrombotic occlusion of central retinal vein at lamina cribrosa; associated with HTN, DM, hyperlipidemia, glaucoma, hypercoagulability | "Blood and thunder" fundus: Widespread flame-shaped and dot-blot hemorrhages across all 4 quadrants, engorged tortuous veins, disc edema, cotton-wool spots | Screen for vascular risk factors, thrombophilia panel (if young/unprovoked: Factor V Leiden, APS, protein C/S deficiency), serum protein electrophoresis | Ophthalmology referral; Intravitreal Anti-VEGF injections (Aflibercept, Ranibizumab) or Dexamethasone intravitreal implants for macular edema; PRP if neovascularization |
| Giant Cell Arteritis (GCA / A-AION) | Immune-mediated granulomatous vasculitis of posterior ciliary arteries supplying optic nerve head; age ≥50 years | Chalky-white, pale, edematous optic disc (Arteritic Anterior Ischemic Optic Neuropathy) with splinter hemorrhages; Relative Afferent Pupillary Defect (RAPD) | Markedly elevated ESR (often >50–100 mm/hr), elevated CRP, thrombocytosis; Temporal Artery Biopsy (≥2–3 cm specimen) | IMMEDIATE High-Dose Systemic Corticosteroids: IV Methylprednisolone 500–1000 mg/day for 3 days, then Oral Prednisone 1 mg/kg/day. DO NOT DELAY STEROIDS FOR BIOPSY (protects contralateral eye); Tocilizumab (anti-IL-6R) |
| Rhegmatogenous Retinal Detachment | Full-thickness retinal tear/hole allowing liquefied vitreous fluid to dissect into subretinal space, peeling neurosensory retina off RPE | Elevated, billowing, folded, gray-white detached retina; loss of normal red reflex; undulating with ocular movement; visible retinal tear/break | Dilated funduscopic exam with indirect ophthalmoscopy; B-scan ocular ultrasonography if media opacified by vitreous hemorrhage | Urgent vitreoretinal surgical intervention: Pneumatic retinopexy, Scleral buckle, or Pars plana vitrectomy; laser barrier photocoagulation for localized tears |
2. Chronic Ophthalmic Diseases for the Internist
Diabetic Retinopathy
Diabetic retinopathy is the leading cause of new blindness among working-age adults (aged 20–74 years) in developed nations.
- Pathophysiology: Chronic hyperglycemia triggers retinal capillary pericyte apoptosis, basement membrane thickening, microvascular leakage, capillary non-perfusion, and tissue ischemia, upregulating Vascular Endothelial Growth Factor (VEGF).
- Clinical Staging & Manifestations:
- Non-Proliferative Diabetic Retinopathy (NPDR):
- Mild/Moderate: Microaneurysms (earliest sign), small dot-and-blot intraretinal hemorrhages, hard lipid exudates (circinate rings), and cotton-wool spots (microinfarctions of the retinal nerve fiber layer).
- Severe NPDR (4-2-1 Rule): Intraretinal hemorrhages in all 4 quadrants, venous beading in ≥2 quadrants, or intraretinal microvascular abnormalities (IRMA) in ≥1 quadrant. High risk of rapid progression to proliferative disease.
- Proliferative Diabetic Retinopathy (PDR):
- Characterized by pathologic neovascularization originating from the optic disc (NVD) or retinal vessels elsewhere (NVE).
- Complications: Preretinal and vitreous hemorrhage (sudden painless vision loss with dark floating streaks), fibrovascular traction causing tractional retinal detachment, and neovascular glaucoma.
- Diabetic Macular Edema (DME): Fluid accumulation and retinal thickening involving the central macula/fovea; can occur at any stage of NPDR or PDR and is the leading cause of moderate visual impairment in diabetics.
- Non-Proliferative Diabetic Retinopathy (NPDR):
- Evidence-Based Management & Screening Guidelines:
- Systemic Optimization: Intensive glycemic control (target HbA1c <7.0%), strict blood pressure control (<130/80 mmHg), and lipid management substantially reduce retinopathy onset and progression (DCCT and UKPDS landmark trials).
- Intravitreal Anti-VEGF Therapy: First-line standard of care for center-involving diabetic macular edema and high-risk PDR (Aflibercept, Ranibizumab, or Faricimab).
- Panretinal Photocoagulation (PRP): Argon laser ablation of ischemic peripheral retina to decrease angiogenic VEGF drive and stabilize proliferative vessels.
- Screening Protocols:
- Type 2 Diabetes: Comprehensive dilated eye examination at the time of initial diagnosis, then annually.
- Type 1 Diabetes: Dilated eye examination within 5 years of diagnosis, then annually.
- Pregnancy in Pre-existing Diabetes: Dilated exam prior to conception or in first trimester, with close trimester monitoring.
Hypertensive Retinopathy
Retinal vascular changes reflect systemic end-organ microvascular damage from acute or chronic hypertension. Staged using the Keith-Wagener-Barker (KWB) Classification:
| KWB Grade | Key Funduscopic Findings | Pathophysiologic Mechanism | Clinical Significance |
|---|---|---|---|
| Grade 1 | Generalized and focal arteriolar narrowing; increased arteriolar light reflex ("copper wiring") | Diffuse arteriolar sclerosis and hypertonus | Chronic mild-to-moderate hypertension |
| Grade 2 | Grade 1 + Arteriovenous (AV) nicking / compression; "silver wiring" (opaque, whitish arteriolar wall) | Thickened sclerotic arteriole wall compresses underlying venule at crossing points | Longstanding sustained hypertension; marker of systemic atherosclerotic burden |
| Grade 3 | Grade 2 + Flame-shaped retinal hemorrhages, cotton-wool spots, hard exudates forming a "macular star" | Breakdown of blood-retinal barrier with focal retinal ischemia and lipid exudation | Moderate-to-severe hypertension; high correlation with stroke and nephrosclerosis |
| Grade 4 | Grade 3 + Papilledema (bilateral optic disc swelling with blurred margins, venous engorgement) | Severe intracranial and microvascular hypertension with axoplasmic flow stasis | Malignant / Hypertensive Emergency; mandates urgent inpatient BP reduction |
Age-Related Macular Degeneration (AMD)
Age-related macular degeneration is the leading cause of irreversible central visual loss in patients aged ≥65 years. Peripheral visual fields remain intact, but central visual acuity (reading, face recognition, driving) is severely impaired.
- Dry (Non-Exudative / Atrophic) AMD (85–90% of cases):
- Pathophysiology: Accumulation of acellular debris beneath the retinal pigment epithelium (RPE) forming focal extracellular yellow deposits known as drusen, progressing to geographic atrophy of the RPE and overlying photoreceptors.
- Symptoms: Gradual, progressive loss of central vision, difficulty reading in low light, and visual distortion (metamorphopsia, detected by wavy/distorted lines on an Amsler grid).
- Management: Smoking cessation is the most critical modifiable lifestyle intervention. Daily supplementation with the AREDS2 antioxidant formula (Vitamin C 500 mg, Vitamin E 400 IU, Zinc oxide 80 mg, Cupric oxide 2 mg, Lutein 10 mg, Zeaxanthin 2 mg — replaces beta-carotene to eliminate lung cancer risk in current/former smokers) reduces the 5-year risk of progression to advanced AMD by 25–30% in patients with intermediate drusen or unilateral advanced AMD. Novel complement C3/C5 inhibitors (Pegcetacoplan, Avacincaptad pegol) slow the rate of geographic atrophy expansion.
- Wet (Exudative / Neovascular) AMD (10–15% of cases, causes 90% of severe blindness):
- Pathophysiology: Pathologic growth of abnormal choroidal neovascular membranes (CNVM) extending through breaks in Bruch's membrane into the sub-RPE or subretinal space. These fragile vessels leak fluid and blood, leading to subretinal hemorrhage, lipid exudation, and eventual disciform fibrovascular scarring.
- Symptoms: Acute or subacute, rapid, painless distortion and severe drop in central vision with central dark blind spots (scotomas).
- First-Line Treatment: Immediate Intravitreal Anti-VEGF Injections (Aflibercept, Ranibizumab, Faricimab, or Bevacizumab) administered on a monthly or treat-and-extend regimen to halt vascular permeability, regress neovascularization, and preserve central vision.
Test Your Knowledge
A 72-year-old man with hypertension and coronary artery disease presents with a sudden, painless loss of vision in his right eye that occurred 45 minutes ago upon waking. Visual acuity is limited to counting fingers at 1 foot in the right eye and 20/20 in the left eye. Pupillary examination reveals a right relative afferent pupillary defect (RAPD). Dilated funduscopic examination reveals diffuse retinal pallor with ischemic whitening throughout the posterior pole and a prominent, well-demarcated cherry-red spot at the fovea. Segmented blood flow ('boxcarring') is visible in the retinal arterioles. Erythrocyte sedimentation rate (ESR) is 18 mm/hr and C-reactive protein is normal. What is the most appropriate next step in management?
A
B
C
D